vs

Side-by-side financial comparison of AST SpaceMobile, Inc. (ASTS) and Health Catalyst, Inc. (HCAT). Click either name above to swap in a different company.

Health Catalyst, Inc. is the larger business by last-quarter revenue ($74.7M vs $54.3M, roughly 1.4× AST SpaceMobile, Inc.). Health Catalyst, Inc. runs the higher net margin — -121.9% vs -136.2%, a 14.3% gap on every dollar of revenue. On growth, AST SpaceMobile, Inc. posted the faster year-over-year revenue change (2758.2% vs -6.2%). Health Catalyst, Inc. produced more free cash flow last quarter ($9.6M vs $-330.7M).

AST SpaceMobile, Inc. is a publicly traded satellite designer and manufacturer based in Midland, Texas, United States. The company is building the SpaceMobile satellite constellation, a space-based cellular broadband network designed to connect directly to standard, unmodified smartphones. The network is intended to deliver 4G and 5G broadband coverage globally, particularly in remote and underserved regions.

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida, United States. The company develops medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS). The drug is referred to under the trade name Firdapse, which was approved by the FDA for approved use in children 6 years and older with LEMS in addition to the prior approval for use in adults with LEMS on November 28, 2018. Fir...

ASTS vs HCAT — Head-to-Head

Bigger by revenue
HCAT
HCAT
1.4× larger
HCAT
$74.7M
$54.3M
ASTS
Growing faster (revenue YoY)
ASTS
ASTS
+2764.3% gap
ASTS
2758.2%
-6.2%
HCAT
Higher net margin
HCAT
HCAT
14.3% more per $
HCAT
-121.9%
-136.2%
ASTS
More free cash flow
HCAT
HCAT
$340.4M more FCF
HCAT
$9.6M
$-330.7M
ASTS

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ASTS
ASTS
HCAT
HCAT
Revenue
$54.3M
$74.7M
Net Profit
$-74.0M
$-91.0M
Gross Margin
Operating Margin
-175.0%
-115.3%
Net Margin
-136.2%
-121.9%
Revenue YoY
2758.2%
-6.2%
Net Profit YoY
-106.3%
-340.3%
EPS (diluted)
$-1.29

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASTS
ASTS
HCAT
HCAT
Q4 25
$54.3M
$74.7M
Q3 25
$14.7M
$76.3M
Q2 25
$80.7M
Q1 25
$79.4M
Q4 24
$79.6M
Q3 24
$76.4M
Q2 24
$75.9M
Q1 24
$74.7M
Net Profit
ASTS
ASTS
HCAT
HCAT
Q4 25
$-74.0M
$-91.0M
Q3 25
$-122.9M
$-22.2M
Q2 25
$-41.0M
Q1 25
$-23.7M
Q4 24
$-20.7M
Q3 24
$-14.7M
Q2 24
$-13.5M
Q1 24
$-20.6M
Gross Margin
ASTS
ASTS
HCAT
HCAT
Q4 25
Q3 25
52.6%
Q2 25
Q1 25
Q4 24
Q3 24
47.5%
Q2 24
Q1 24
Operating Margin
ASTS
ASTS
HCAT
HCAT
Q4 25
-175.0%
-115.3%
Q3 25
-1109.0%
-22.9%
Q2 25
-46.0%
Q1 25
-25.4%
Q4 24
-22.0%
Q3 24
-17.9%
Q2 24
-20.8%
Q1 24
-30.5%
Net Margin
ASTS
ASTS
HCAT
HCAT
Q4 25
-136.2%
-121.9%
Q3 25
-833.7%
-29.1%
Q2 25
-50.8%
Q1 25
-29.9%
Q4 24
-26.0%
Q3 24
-19.3%
Q2 24
-17.8%
Q1 24
-27.6%
EPS (diluted)
ASTS
ASTS
HCAT
HCAT
Q4 25
$-1.29
Q3 25
$-0.32
Q2 25
$-0.59
Q1 25
$-0.35
Q4 24
$-0.33
Q3 24
$-0.24
Q2 24
$-0.23
Q1 24
$-0.35

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASTS
ASTS
HCAT
HCAT
Cash + ST InvestmentsLiquidity on hand
$4.3B
$95.7M
Total DebtLower is stronger
$153.3M
Stockholders' EquityBook value
$2.4B
$245.8M
Total Assets
$5.0B
$502.6M
Debt / EquityLower = less leverage
0.62×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASTS
ASTS
HCAT
HCAT
Q4 25
$4.3B
$95.7M
Q3 25
$2.4B
$91.5M
Q2 25
$97.3M
Q1 25
$342.0M
Q4 24
$392.0M
Q3 24
$387.3M
Q2 24
$308.3M
Q1 24
$327.8M
Total Debt
ASTS
ASTS
HCAT
HCAT
Q4 25
$153.3M
Q3 25
$153.1M
Q2 25
$153.0M
Q1 25
$382.9M
Q4 24
$382.4M
Q3 24
$345.0M
Q2 24
Q1 24
Stockholders' Equity
ASTS
ASTS
HCAT
HCAT
Q4 25
$2.4B
$245.8M
Q3 25
$1.6B
$331.9M
Q2 25
$347.5M
Q1 25
$376.8M
Q4 24
$365.2M
Q3 24
$355.0M
Q2 24
$357.0M
Q1 24
$357.2M
Total Assets
ASTS
ASTS
HCAT
HCAT
Q4 25
$5.0B
$502.6M
Q3 25
$2.6B
$587.1M
Q2 25
$616.2M
Q1 25
$891.5M
Q4 24
$858.9M
Q3 24
$813.0M
Q2 24
$691.7M
Q1 24
$695.1M
Debt / Equity
ASTS
ASTS
HCAT
HCAT
Q4 25
0.62×
Q3 25
0.46×
Q2 25
0.44×
Q1 25
1.02×
Q4 24
1.05×
Q3 24
0.97×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASTS
ASTS
HCAT
HCAT
Operating Cash FlowLast quarter
$65.0M
$9.9M
Free Cash FlowOCF − Capex
$-330.7M
$9.6M
FCF MarginFCF / Revenue
-609.0%
12.9%
Capex IntensityCapex / Revenue
728.7%
0.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-790.4M
$-697.0K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASTS
ASTS
HCAT
HCAT
Q4 25
$65.0M
$9.9M
Q3 25
$-64.5M
$-464.0K
Q2 25
$-9.0M
Q1 25
$280.0K
Q4 24
$-3.5M
Q3 24
$6.2M
Q2 24
$1.6M
Q1 24
$10.3M
Free Cash Flow
ASTS
ASTS
HCAT
HCAT
Q4 25
$-330.7M
$9.6M
Q3 25
$-302.9M
$-719.0K
Q2 25
$-9.2M
Q1 25
$-390.0K
Q4 24
$-3.9M
Q3 24
$5.5M
Q2 24
$1.3M
Q1 24
$10.1M
FCF Margin
ASTS
ASTS
HCAT
HCAT
Q4 25
-609.0%
12.9%
Q3 25
-2055.0%
-0.9%
Q2 25
-11.4%
Q1 25
-0.5%
Q4 24
-4.9%
Q3 24
7.2%
Q2 24
1.7%
Q1 24
13.5%
Capex Intensity
ASTS
ASTS
HCAT
HCAT
Q4 25
728.7%
0.4%
Q3 25
1617.6%
0.3%
Q2 25
0.3%
Q1 25
0.8%
Q4 24
0.5%
Q3 24
0.9%
Q2 24
0.4%
Q1 24
0.3%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ASTS
ASTS

Products$44.4M82%
Other$7.8M14%
Sat Co$2.1M4%

HCAT
HCAT

Recurring Technology$51.9M69%
Professional Services$22.8M31%

Related Comparisons